GSK launches hostile $2.6 bn bid for Human Genome Sciences

May 9, 2012

British drugmaker GlaxoSmithKline on Wednesday said it had gone hostile over its $2.6 billion (2.0 billion-euro) takeover bid for US research partner Human Genome Sciences Inc.

GlaxoSmithKline, which in April had an informal offer rejected by the US company's board, said it had decided to put its bid directly to the shareholders of HGS. The offer remains $13 per share in cash.

" today announced that it will ... commence a tender offer this week to acquire all of the outstanding shares of HGS for $13.0 per share in cash," the British firm said.

"GSK's offer represents a premium of 81 percent to HGS's closing share price of $7.17 on 18th April, the last trading day before HGS publicly disclosed GSK's private offer."

Explore further: Roche extends its hostile takeover bid for Illumina

Related Stories

GlaxoSmithKline says net profits drop 13% in Q1

April 25, 2012

British drugsmaker GlaxoSmithKline said Wednesday that its net profits dropped 13 percent to £1.325 billion (1.616 billion euros, $2.134 billion) in the first quarter from a year earlier.

Recommended for you

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.